Hormonal
GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) reduce cancer risk in overweight/obese individuals primarily through sustained weight loss and secondarily through weight-loss-independent anti-inflammatory and metabolic mechanisms.
For individuals with obesity, GLP-1/GIP agonists (like semaglutide or tirzepatide) are more effective than diet alone for achieving sustained weight loss, which is linked to reduced cancer risk. These medications work by reducing hunger and improving metabolic health. While they require ongoing use and can be costly, they offer a clinically significant advantage over lifestyle changes alone for those who struggle with long-term adherence.
These agents are increasingly used to lose weight, resulting in weight loss-dependent as well as weight loss-independent effects that may impact cancer risk.
Why this rating
The paper is a review of observational and RCT data, noting conflicting signals (e.g., thyroid cancer risk) and a need for long-term studies.
Source
Mechanisms by Which Pharmacotherapy May Impact Cancer Risk among Individuals with Overweight and Obesity
Edward R. Sauter et al. · Cancers · 2024
DOI 10.3390/cancers16193275
More from this paper
- Sustained weight loss of at least 5% achieved through pharmacotherapy or bariatric surgery is associated with a reduced risk of obesity-related cancers.Good
- GLP-1 receptor agonists may increase the risk of thyroid cancer (specifically medullary thyroid cancer) and biliary tract disease, requiring monitoring despite potential cancer benefits.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →